Although AKT mutations play a significant role in ER+ and PR+ tumors, little is known about their role in HER2+ BC, particularly given that AKT1 mutations are only observed in tumors co-expressing ER and PR [41]. The gene discussed is ERBB2; the disease is breast cancer.